This page has been fact checked by an experienced mesothelioma Patient Advocate. Sources of information are listed at the bottom of the article.
We make every attempt to keep our information accurate and up-to-date.
Please Contact Us with any questions or comments.
Dr. William Petty is a medical oncologist and hematologist in the department of Medical Oncology at the Wake Forest Medical Center and Wake Forest Comprehensive Cancer Center. As Director of the Thoracic Oncology program, he specializes in treating patients diagnosed with lung cancer and malignant pleural mesothelioma.
Dr. Petty’s philosophy on taking care of patients with lung cancer is to try to understand the patient first, to understand where they are in their lives, where their families are, as well as where the disease is. He says, “Sometimes the challenges with facing lung cancer have to do not only with the prognosis but also the prospect of taking on treatments and what that means for a patient and their family. I try to provide the best care for every patient, but that’s different for every patient.”
Education and Career
Dr. Petty earned his bachelor of arts degree at Harvey Mudd College, then earned his medical degree at the University of North Carolina at Chapel Hill School of Medicine. He completed his internship and residency in Internal Medicine at Duke University Hospital and followed that program with a fellowship in Medical Oncology at Mary Hitchcock Memorial Hospital at the Dartmouth Cancer Center.
Dr. Petty is board-certified in Internal Medicine and Medical Oncology. In addition to his medical practice, he is a Professor of Hematology and Oncology and an Associate Professor of Cancer Biology at the Bowman Gray School of Medicine of Wake Forest University.
Dr. Petty’s research interest began with investigating new strategies for treating lung cancer through the study of cell culture models and other bench laboratory techniques. That early work prepared him for today’s innovations in the treatment of lung cancer, including understanding the genetics of a cancer and how a cancer develops so that its weaknesses can be targeted.
- American Society of Clinical Oncology
- American Association of Cancer Research
- American College of Chest Physicians
Written by Terri Oppenheimer
Terri Oppenheimer has been writing about mesothelioma and asbestos topics for over ten years. She has a degree in English from the College of William and Mary. Terri’s experience as the head writer of our Mesothelioma.net news blog gives her a wealth of knowledge which she brings to all Mesothelioma.net articles she authors.
Page Edited by Patient Advocate Dave Foster
Dave has been a mesothelioma Patient Advocate for over 10 years. He consistently attends all major national and international mesothelioma meetings. In doing so, he is able to stay on top of the latest treatments, clinical trials, and research results. He also personally meets with mesothelioma patients and their families and connects them with the best medical specialists and legal representatives available.